



## **Sigilon Therapeutics to Participate in Three Upcoming Investor Conferences**

August 7, 2020

**CAMBRIDGE, Mass., August 7, 2020** – Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.

### **Presentation Details:**

**Event:** BTIG Virtual Biotechnology Conference

**Date:** Monday, August 10, 2020

**Time:** 9:00 AM ET

**Details:** Fireside chat

**Event:** Canaccord Genuity 40th Annual Growth Conference

**Date:** Thursday, August 13, 2020

**Time:** 1:30 PM ET

**Details:** Corporate presentation

**Event:** Oppenheimer Private Life Sciences Company Call Series

**Date:** Wednesday, August 19, 2020

**Time:** 9:30 AM ET

**Details:** Corporate presentation

### **About Sigilon Therapeutics**

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

### **Investor Contact**

Glenn Reicin

Sigilon Therapeutics, Chief Financial Officer

glenn.reicin@sigilon.com

646-696-4344

### **Media Contact**

Amy Bonanno

Solebury Trout

abonanno@troutgroup.com

914-450-0349